Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of FRSW107 in Hemophilia A
NCT04456387Phase 3Completed
- Sponsor
- Zhengzhou Gensciences Biotechnology Co Ltd
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 3, open-label trial in hemophilia A (2 arms), sponsored by Zhengzhou Gensciences Biotechnology Co Ltd. Primary endpoints: Score of bleeding symptoms at 6 months, Annualized Bleeding Rates at 6 months and 1 more. Started Oct 2020; status: completed.
02
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04456387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456387.